Theriva Biologics (TOVX) has released an update.
The continuation of the VIRAGE clinical trial, a Phase 2b study for a new pancreatic cancer therapy, has been endorsed by experts after a positive review of its safety and feasibility. This trial tests VCN-01, an innovative treatment combined with standard chemotherapy, and has shown promise with no new toxicities observed, even after a second dose. The trial is proceeding smoothly and is expected to finish enrolling patients by mid-2024.
For further insights into TOVX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
